

(Rs. In Lacs)

	Particulars					CONSOLIDATED
		Quarter Ended on 31 st March 2011	Quarter Ended on 31 st March 2010	Year Ended on 31 st March 2011	Year Ended on 31 st March 2010	Previous Accounting year ended on 31st March 2010
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	(a) Net Sales / Income from Operations					
	Domestic	4593	17016	19443	70360	70360
	Exports	774	8757	2248	32846	44509
	Total	5367	25773	21691	103206	114869
	Less : Excise Duty	387	352	1613	1054	1054
	Net Sales / Income from Operations	4980	25421	20078	102152	113815
	(b) Other Operating Income	71	50	115	262	262
	Total Income	5051	25471	20193	102414	114077
2	Expenditure					
	(a) Decrease/(increase) in stock in trade and work in progress	538	-607	369	221	221
	(b) Consumption of Raw Materials & Packing Materials	2627	10722	12639	35051	35051
	(c) Purchase of traded goods	0	2188	70	11737	21265
	(d) Employees' Cost	596	3599	2692	14547	14547
	(e) Research and Development Expense	20	1094	184	4327	4327
	(f) Excise Duty	-40	280	-21	565	565
	(g) Other Expenditure	887	6590	3959	26472	26581
	Total	4628	23866	19892	92920	102557
3	Profit from Operations before Other Income, Interest, Depreciation	423	1605	301	9494	11520
	Exceptional Items					
4	Other Income	60	56	262	168	168
5	Profit/(Loss) before Interest, Depreciation, & Exceptional Items	483	1661	563	9662	11688
6	Depreciation	-215	1100	1007	4302	4302
7	Interest (Net)	97	619	240	3005	3005
8	Profit/(Loss) after Interest but before Exceptional Items	601	-58	-684	2355	4381
9	Exceptional Items - Voluntary Retirement Scheme	54	-	422	0	0
10	Net Profit / (Loss) from Ordinary Activities before Tax	547	-58	-1106	2355	4381
11	Tax Expense					
	Less : Provision for Wealth Tax	3	3	13	13	13
	Less : Provision for Current Tax	0	-32	-	376	516
	Less/(Add) : Provision for Deferred Tax Liability/(Assets)	125	-7	-105	-102	-102
	Less/(Add) : Provision of Income Tax of earlier years written back (Net)	277	-	276	-	0
12	Net Profit / (Loss) from Ordinary Activities after Tax	142	-22	-1290	2068	3954
13	Paid up Equity Share Capital (Face value of share Rs 2/-)	2670	2670	2670	2670	2670
14	Reserves excluding Revaluation Reserve	-	-	6234	28903	31142
15	Debenture Redemption Reserve	-	-	-	1542	1542
16	Basic & Diluted EPS (Not Annualised)	0.11	-0.02	-0.97	1.53	2.93
17	Debt Equity Ratio	-	-	-	0.71	0.77
18	Debt Service Coverage Ratio	-	-	-	1.41	1.72
19	Interest Service Coverage Ratio	-	-	-	3.61	4.40
20	Public Shareholding					
	- Number of Shares	48763089	48762909	48763089	48762909	48762909
	- Percentage of Shareholding	36.52	36.52	36.52	36.52	36.52
21	Promoters and Promoter Group Shareholding					
	(a) Pledged / Encumbered					
	Number of Shares	-	-	-	-	-
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	Percentage of Shares (as a % of the total share capital of the Company)	-	-	-	-	-
	(b) Non - Encumbered					
	Number of Shares	84752825	84753005	84752825	84753005	84753005
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	Percentage of Shares (as a % of the total share capital of the Company)	63.48	63.48	63.48	63.48	63.48



Notes :

- 1 The above results have been duly audited by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors.
- 2 In pursuance of Honourable Gujarat High Court's Order, the Pharmaceutical Undertaking of the Company is demerged and transferred to Alembic Pharmaceuticals Limited w.e.f. appointed date 1st April 2010. Accordingly, above results do not include results of said pharmaceutical undertaking. As a result of such transfer of business, current quarter's/year's figures are not comparable with the previous quarter/year.

The previous year's figures have been rearranged wherever necessary.
- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 As per the Scheme of Arrangement approved by Honourable Gujarat High Court on 24/1/2011, Fixed Assets of Vadodara Undertaking of the Company have been revalued. Subsequent to the revaluation, depreciation on the Assets has been provided for on the net revalued amount prospectively over the remaining balance of original life and such reworked depreciation results in writing back of depreciation of Rs.215 lacs in the last quarter ended 31/3/2011 in respect of period ended 31/12/2010.
- 5 Alembic Pharmaceuticals Limited(APL) was wholly owned subsidiary of the Company as on 31/3/2011. Consequent upon allotment of 13,35,15,914 equity shares of Rs.2/- each to the shareholders of Alembic Limited on 15/4/2011, as per the Scheme of Arrangement, the shareholding of the Company in APL has reduced from 100% to 29.18%. Since the Scheme of Arrangement is effective from the appointed date i.e. 01/04/2010 pursuant to the order of the Hon'ble High Court, the results of APL have not been consolidated with the Company's results.
- 6 Details of Investors' Complaints for the quarter ended on 31st March, 2011 : Unresolved at the beginning of the quarter-NIL Received during the quarter-02, Disposed off during the quarter-02 , Unresolved at the end of the quarter - NIL.

Place : Vadodara
Date : 2nd May, 2011

Visit us at www.alembiclimited.com

For Alembic Limited



Chirayu Amin
Chairman

